	US 11,884,709 B2
	Peptides for the treatment of resorptive bone disease
Alli Murugesan, Saint John (CA); and Anthony Reiman, Saint John (CA)
Assigned to University of New Brunswick, Fredericton (CA)
Filed by University of New Brunswick, Fredericton (CA)
Filed on Feb. 17, 2021, as Appl. No. 17/177,771.
Application 17/177,771 is a division of application No. 15/773,065, granted, now 10,954,278, previously published as PCT/CA2016/051273, filed on Nov. 2, 2016.
Claims priority of provisional application 62/249,471, filed on Nov. 2, 2015.
Prior Publication US 2021/0253653 A1, Aug. 19, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/10 (2006.01); A61P 19/08 (2006.01); C07K 14/47 (2006.01); A61K 38/00 (2006.01)

CPC C07K 14/4703 (2013.01) [A61K 38/10 (2013.01); C07K 14/47 (2013.01); A61K 38/00 (2013.01)]

20 Claims

1. A method for treating resorptive bone disease in a subject in need thereof, comprising administering to the subject a peptide consisting essentially of the amino acid sequence with at least 90% identity to the amino acid sequence of KEFLHPSKVDLPR (SEQ ID NO:1) or at least 95% identity to the amino acid sequence of EGKLSSNDTEGGLCKEFLHPSKVDLPR (SEQ ID NO: 2).